Articles

Between 2014 and 2060, the population of Americans aged ≥65 years is projected to more than double, ushering in a transformation of our workforce, healthcare system, and understanding of aging.¹ This generation, and those following, are expected to live longer and remain more active. Every day, the average life span increases by >5 hours, and a growing number of Americans at retirement age choose to continue working full-time.^2,3 Unfortunately, with age comes higher rates of chronic illness, including cancer.⁴ In 2016, individuals aged ≥65 years represented 62% of all 15.5 million cancer survivors in the United States, and by 2040, they are expected to represent 73% of a projected 26.1 million cancer survivors.⁵ Read More ›

The Cedars-Sinai Blood & Marrow Transplant Program, Los Angeles, CA, has performed more than 2200 stem-cell and bone marrow transplants since its inception in 1990. The program is accredited for autologous and allogeneic transplant by the Foundation for the Accreditation of Cellular Therapy and is a National Marrow Donor Program/Be The Match Transplant Center. It has also been recognized as a Blue Cross Center of Medical Excellence, a designation awarded to select hospitals that meet evidence-based standards and provide high-quality care for patients. Read More ›

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. Read More ›